Medpace Holdings, Inc. (MEDP) — ESG & Values Scores

Environment story

Medpace discloses substantial environmental compliance and operational safety protocols but provides minimal quantitative emissions data. The company states it believes it is in substantial compliance with all applicable environmental laws and has no material environmental liabilities. However, Scope 1, Scope 2, and Scope 3 emissions are entirely undisclosed, net-zero targets are not stated, and renewable energy percentage is not reported. The company operates laboratories and clinical facilities with hazardous materials and medical waste disposal, creating inherent environmental risk. Without disclosed emissions baselines, reduction targets, or net-zero commitments, environmental scoring reflects regulatory compliance posture rather than proactive decarbonization strategy.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Environmental Compliance & Regulatory Adherence

Company states substantial compliance with all applicable environmental laws and regulations governing hazardous substances, waste disposal, and workplace safety. Operations include use, generation and disposal of hazardous materials and medical wastes with established management procedures.

Reduces environmental liability risk but does not constitute active decarbonization or emissions reduction strategy.
Occupational Health & Safety Program

Reported 'extremely low incident rates' with robust incident reporting procedures for work-related injuries and illnesses. Facilities equipped with access control systems, on-site security, First Aid/CPR/Fire Warden training programs.

Mitigates direct operational safety risk but is not an environmental emissions or resource-conservation initiative.

Social story

Medpace demonstrates strong workforce diversity metrics and active labor-relations stability. Women comprise 66% of global workforce and 52% of director-level positions; 17% of U.S. employees are non-white. No collective bargaining agreements exist for the company, and no documented union-suppression activities, major strikes, or NLRB complaints are disclosed within the 24-month window. CEO-to-median-worker pay ratio is not disclosed, preventing full assessment against the 200:1 threshold. The company emphasizes merit-based advancement, anti-discrimination policies, and robust recruitment/retention programs with 75% of management-level roles filled internally. Supply-chain human-rights audit mechanisms and living-wage commitments are not disclosed. Overall social score reflects positive diversity outcomes and labor peace, with data gaps around executive compensation and supply-chain ethics.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Diversity & Inclusion Commitment

Strong record of hiring and advancing women at all organizational levels. Company committed to maintaining respectful work environment with equal opportunity and fair treatment regardless of gender, race, color, creed, religion, family status, age, national origin, disability, veteran status, citizenship, sexual orientation, or gender identity. Anti-discrimination, anti-harassment, and anti-retaliation policies embedded in Medpace Code of Conduct.

Supports inclusive talent pipeline; women represent 66% of workforce and 52% of director+ positions.
Recruitment, Retention & Career Development

Centralized hiring and training with global learning management system tracking regulatory compliance and training delivery. Robust career paths and compensation structure recognizing performance at all levels. 75% of management-level roles filled by internal talent pipeline (Oct 2024–Sep 2025). Competitive benefits packages tailored to diverse workforce needs across 46 countries.

High internal promotion rate and employee loyalty reduce turnover and support operational stability.
Workplace Safety & Health

Robust incident reporting for work-related injuries and illnesses. Lab operations comply with all Health & Safety requirements. Physical security systems, on-site personnel in key offices, First Aid/CPR/Fire Warden training. Company reports 'extremely low incident rates.'

Reduces occupational health risk and supports employee well-being.

Governance story

Medpace exhibits material governance concerns centered on founder/CEO control concentration. Dr. Krishnan Rajagopal, founder and CEO, controls a substantial amount of outstanding common stock, creating potential for interest misalignment with minority shareholders. The 10-K explicitly identifies this as a structural and organizational risk factor. Board independence percentage is not disclosed, preventing full assessment against the 75% threshold. The company discloses no active lobbying designed to weaken climate regulation or consumer-protection statutes. No significant antitrust, consumer-safety, or financial-fraud regulatory proceedings are documented. Related-party transactions exist but are not detailed as contested. Overall governance score reflects dual-class/founder-control risk offset by absence of major regulatory violations or deregulatory lobbying.

Criticisms on file

Founder/CEO Control Concentration: Dr. Krishnan Rajagopal, founder and Chief Executive Officer, controls a substantial amount of outstanding common stock. Risk factor identifies potential for his interests to differ from or conflict with other shareholders.
Source: MEDP 10-K, Item 1A Risk Factors, 'Structural and Organizational Risks' section

Disclosed initiatives

Regulatory Compliance & Governance Framework

Company demonstrates compliance with FDA, EMA, MHRA, and Health Canada regulations for clinical trial conduct. Adherence to Good Clinical Practice (GCP), International Council on Harmonisation (ICH) guidelines, HIPAA privacy rules, Foreign Corrupt Practices Act (FCPA), UK Bribery Act, and Clinical Laboratory Improvement Amendments (CLIA). Mandatory anti-corruption training and safeguards to prevent unauthorized payments by employees and business partners.

Establishes regulatory baseline and reduces risk of material compliance violations.
Code of Conduct & Ethics

All employees subject to Medpace Code of Conduct forming foundation of personnel and ethics policies. Anti-discrimination, anti-harassment, and anti-retaliation policies applicable to all employees. Employees responsible for upholding conduct standards.

Supports ethical culture and reduces misconduct risk.
Data Security & Privacy Controls

Range of information technology solutions, controls, procedures, and processes designed to protect confidentiality, integrity, and availability of critical assets and data. Limited cyber-insurance coverage with deductibles and exclusions. Measures aimed at preventing data breaches and minimizing remediation if breach occurs.

Mitigates breach risk but insurance coverage limitations noted as a gap.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Medpace Holdings, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Medpace Holdings, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)